2 min read

$SYRE: Two Scanner Signals, One Month, +69% — How It Played Out

EverHint scanner flagged $SYRE twice: Dip Bounce reclaim at $44.07 on March 16, Momentum Swing breakout at $68.99 on April 15. Today it's trading at $74.50, near its 52-week high. Here's what the data showed at each signal.
$SYRE: Two Scanner Signals, One Month, +69% — How It Played Out
Spyre Therapeutics Inc
$SYRE$S

The Timeline

March 16, 2026Dip Bounce V2 Reclaim flagged SYRE at $44.07 (RECLAIM_LONG). The stock had been basing after a pullback and showed early signs of reclaiming a key level. At the time, this was a recovery signal — not yet a momentum play.

April 15, 2026Momentum Swing (Volatile High Beta) flagged SYRE at $68.99 — ranked #1 out of 5 signals with a perfect composite score of 1.000 and 3.46x volume thrust. The stock had already run +57% from the March signal. SPY001 Phase 2 data in ulcerative colitis had just dropped, Raymond James initiated Strong Buy, and the company priced a $403M upsized public offering.

April 17, 2026 — SYRE is trading at $74.50 (+6.88% today), touching its 52-week high of $75.00. That's +69% from the March 16 flag and +8% from the April 15 flag.


What the Scanner Saw

The first signal (Dip Bounce) caught the early recovery — a technical reclaim before the fundamental catalysts materialized. The second signal (Momentum Swing) caught the continuation after catalysts confirmed. Two different strategies, same stock, both identifying actionable inflection points.

Worth noting: the April 15 signal ranked SYRE #1 despite $1.5M in insider selling and a pre-clinical stage company with negative EPS. The volume thrust (3.46x average) and momentum score overrode those caution flags — correctly, as it turned out.


Current Analyst Picture

  • 15 out of 15 analysts rate SYRE as Buy or Outperform
  • Consensus target: $81.90 (+10% from current price)
  • Range: $49.00 – $106.00
  • Recent actions: Raymond James initiated Strong Buy (Apr 13), Wells Fargo maintained Overweight (Apr 14), Deutsche Bank maintained Buy (Apr 14)

The offering closed at $463.5M (upsized from $403M with full greenshoe exercise), which funds the pipeline runway through multiple 2026 readouts.


Honest Assessment

The scanner doesn't get every call right — and this is one stock, not a portfolio. But SYRE is a clean example of what happens when technical signals align with fundamental catalysts across multiple timeframes.

The Dip Bounce caught the setup. The Momentum Swing caught the confirmation. The data was there both times.


Not financial advice. Always do your own due diligence.
See https://www.everhint.com/disclaimer/


EverHint — Independent, data-driven signals.